Physician profile
Michael Laufer
NPI 1164493946
$7,149.61
in general payments reported to CMS, 2019-2025
33 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $990 · 2021: $1,815 · 2022: $979 · 2023: $1,110 · 2024: $903 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $810.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $753.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $567.44 | 2019-2024 | |
| Amarin Pharma, INC. | $551.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $528.67 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Abbvie INC. | $477.64 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $458.41 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $441.61 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $440.30 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $410.17 | 2019-2024 | Repatha, Otezla, Prolia |
| Kowa Pharmaceuticals America, INC. | $373.07 | 2019-2025 | Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.29 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $179.86 | 2019-2025 | |
| Astellas Pharma US INC | $110.20 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $80.09 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $72.67 | 2023-2024 | Watchman Flx |
| Allergan, INC. | $65.68 | 2019-2020 | |
| Insulet Corporation | $61.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.35 | 2019-2022 | |
| Almatica Pharma LLC | $45.29 | 2021-2023 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $44.66 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $43.01 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.68 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $24.66 | 2025 | Gemtesa |
| Scilex Pharmaceuticals INC. | $23.03 | 2021 | |
| Exact Sciences Corporation | $18.42 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $17.41 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $17.01 | 2025 | Vyepti |
| Corcept Therapeutics | $16.90 | 2025 | Korlym |
| Horizon Therapeutics Plc | $15.66 | 2023 | Krystexxa |
| Medtronic, INC. | $15.64 | 2025 | Venaseal |
| Eisai INC. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Laufer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.